4,075 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by James Investment Research Inc.

James Investment Research Inc. purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,075 shares of the specialty pharmaceutical company’s stock, valued at approximately $243,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. New York State Teachers Retirement System lifted its position in ANI Pharmaceuticals by 1.7% during the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of ANI Pharmaceuticals by 64.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 1,582 shares during the period. State of Alaska Department of Revenue raised its position in shares of ANI Pharmaceuticals by 5.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after acquiring an additional 464 shares during the period. Louisiana State Employees Retirement System raised its holdings in ANI Pharmaceuticals by 3.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock worth $477,000 after buying an additional 300 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in ANI Pharmaceuticals by 149.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock worth $11,107,000 after buying an additional 111,613 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ANIP shares. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Raymond James lifted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Finally, Truist Financial boosted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $58.19 on Friday. The stock has a market cap of $1.22 billion, a P/E ratio of 49.74 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The stock’s 50-day moving average is $59.13 and its 200-day moving average is $61.79. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same period in the prior year, the business posted $1.06 earnings per share. The firm’s revenue was up 18.5% on a year-over-year basis. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.51 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.